The Independent Market Observer

Financial Markets Hold Gains on Vaccine and Stimulus News

Posted by Brad McMillan, CFA®, CFP®

Find me on:

This entry was posted on Jan 14, 2021 4:14:25 PM

and tagged Commentary

Leave a comment

coronavirusAs expected, we saw infections due to holiday travel showing up in the data over the past week, with case counts rising to new highs. But by week’s end, there were signs that case growth was peaking as the holiday travel effects started to fade. We could now be approaching the peak, although the events in Washington on January 6 are now presenting a risk of another wave of travel-induced infections. We should know in the next week or so if that is the case.

The real area of improvement this week has been in vaccine deployment. Vaccinations have accelerated significantly since the start of the year, and we now have more than 3 percent of the population vaccinated. With current trends, we should have about half the population vaccinated by the end of March. As the vaccinated population grows along with the population of people who have been exposed to the virus, that should also help reduce infection rates. We are getting close to the worst of it. After that point, more improvement should come steadily.

The economic news also continued to deteriorate, but here too we saw positive signs. Confidence and spending were down as lockdowns widened around the country. On the positive side, the federal government has now passed a stimulus program that should help support the economy over the next couple of months. And with the new administration, more stimulus is likely.

While the current headlines continue to be bad, there are signs of improvement and reasons to believe we are close to the bottom. That seems to be what markets are thinking, as a combination of slowly decreasing medical risks and economic resiliency has kept them close to all-time highs in the past weeks. Let’s take a look at the details.

Christmas Travel Cases May Be Peaking

New cases per day. The most obvious metric for tracking the virus is daily new cases. We saw a data distortion lull in the aftermath of the Christmas holiday, as we did with Thanksgiving, with the drop due to slower data reporting. Now, however, case growth has moved back up to new highs as the holiday travel surge shows up. With that said, we are now two weeks past the new year. Much of the travel infections are likely already in the system, which may be shown by the infection peak in the past couple of days. While risks remain—the events of January 6 in Washington could result in another round of infection growth—we may be getting close to the crest of the third wave.

New daily infection rates were 236,631 on January 13, down from 265,105 a week earlier. The seven-day average number of new cases per day was 250,092, up from 229,523 a week ago, a smaller increase than in the prior week. While case growth remains high, the good news is that the rate of increase looks to have slowed. If this trend continues, we could see the third wave peak in the next couple of weeks, as the post-holiday surge fades.



Death rate. The death rate reporting is also showing the same trends. This is a lagging indicator and runs from six to eight weeks behind case growth. As such, recent increases in the death rate reflect infection growth in late November and early December. On a seven-day moving average basis, daily deaths were at 3,419 on January 13, up from 2,702 in the prior week. As the number of new cases has spiked since Christmas, we can reasonably expect death rates to increase substantially over the coming weeks.



Testing. Finally, we see that the testing news is showing improvement. Daily testing rose again, after a pullback, and positive rates have started to decline. This could be a leading indicator of improvements.


Source: Johns Hopkins University

The bottom line is that while the data has continued to get worse, driven by holiday travel infections, there are signs we are through the worst of it as infection growth has slowed and positive testing rates ticked down. We could therefore see more improvement in the next couple of weeks. Along with the deployment of vaccines, we may be approaching the end of the beginning. While the pandemic may well look worse over the next couple of weeks, the medium- and longer-term pictures look brighter.

Pandemic Economic Damage Continues

Jobs and consumers. Government-mandated shutdowns in response to the deterioration of the medical situation, along with changes in consumer behavior, have hit the economy hard in recent weeks. Job growth went negative for December, and layoffs have risen again. Most affected are workers in the leisure and hospitality industries. With the employment market down, consumer confidence has softened further, leading to a sharp drop in retail spending as reported for last month. Overall, the data suggests that the third wave has now hit a point where it is acting as a significant drag on the economy, and that will last until medical conditions improve.



Business sector. Despite the slowing in the consumer economy, based on what we know so far, the business sector continues to do well. Business confidence and investment remain at pre-pandemic levels, although the risks here are rising as well.

The real question, going forward, is how durable this recovery is. Much of the data has remained solid despite the ongoing third wave, suggesting substantial resilience. The question is whether the accelerating damage will reverse the economic recovery before the vaccines can be widely deployed. Here, the fiscal stimulus package passed by Congress should help bridge that gap. It will provide the kind of boost that supported growth in earlier waves, especially in the low-wage populations most at risk, which should get us through until vaccines start to make a difference. At that point, we should start to see consumer confidence and spending bounce back, as we saw after previous waves. While the risks are real, the federal stimulus will substantially mitigate the worst of them.

Financial Markets Hold Gains on Vaccine and Stimulus News

Markets continued to rally and hit all-time highs again. Reasons this week are both the existing federal stimulus package and the expectation of more federal stimulus shortly. Both medical and economic risks now look to be close to peaking, and it is reasonable to conclude we are at the end of the beginning of the pandemic. Between the short-term cushion from the stimulus and the expectation that vaccines will normalize the medical risks in 2021, markets are clearly looking for a much better 2021—and prices are responding.

The Road Ahead

While we are not yet through the third wave, there are signs a crest may be approaching as holiday travel effects fade. Similarly, while the economic damage continues, the federal stimulus should help mitigate the damage until the medical risks decline. The good news is that vaccines are now starting, and there are signs that policy is starting to succeed in containing the virus. So, despite the short-term damage done by holiday travel, the medical risks may be within weeks of peaking.

Similarly, while the economic news continues to be worrying, the federal government’s stimulus bill should provide enough cushion for the economy to keep growing until the medical risks are more contained. The most likely case for the next couple of weeks appears to be stabilization of the medical news, with possible slow improvement. Similarly, the economic data will remain soft in the short term but should then show improvement as the stimulus package takes effect. Markets will likely keep bouncing around on new developments, so expect more volatility in the short term.

In the longer term, the good news is that vaccines are now rolling out increasingly quickly. In a few months, we should be approaching the end of the pandemic when the economy can normalize and start to really grow again. The stimulus package should help the economy bridge the gap to that point. Despite the headlines we are seeing today and the real risks, we are making progress. We will get there—but it will just take a bit longer.

Subscribe via Email

New call-to-action
Crash-Test Investing

Hot Topics

New Call-to-action



see all



The information on this website is intended for informational/educational purposes only and should not be construed as investment advice, a solicitation, or a recommendation to buy or sell any security or investment product. Please contact your financial professional for more information specific to your situation.

Certain sections of this commentary contain forward-looking statements that are based on our reasonable expectations, estimates, projections, and assumptions. Forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Past performance is not indicative of future results. Diversification does not assure a profit or protect against loss in declining markets.

The S&P 500 Index is a broad-based measurement of changes in stock market conditions based on the average performance of 500 widely held common stocks. All indices are unmanaged and investors cannot invest directly in an index.

The MSCI EAFE (Europe, Australia, Far East) Index is a free float‐adjusted market capitalization index that is designed to measure the equity market performance of developed markets, excluding the U.S. and Canada. The MSCI EAFE Index consists of 21 developed market country indices.

One basis point (bp) is equal to 1/100th of 1 percent, or 0.01 percent.

The VIX (CBOE Volatility Index) measures the market’s expectation of 30-day volatility across a wide range of S&P 500 options.

The forward price-to-earnings (P/E) ratio divides the current share price of the index by its estimated future earnings.

Third-party links are provided to you as a courtesy. We make no representation as to the completeness or accuracy of information provided on these websites. Information on such sites, including third-party links contained within, should not be construed as an endorsement or adoption by Commonwealth of any kind. You should consult with a financial advisor regarding your specific situation.


Please review our Terms of Use

Commonwealth Financial Network®